Novo Nordisk faces mounting investor pressure to expand its pharmaceutical pipeline beyond blockbuster obesity treatments. As the company prepares for its shareholder meeting, stakeholders are demanding strategic acquisitions and innovation in drug development. The pharmaceutical giant must balance its current market dominance with long-term growth strategies to maintain investor confidence and competitive positioning in the evolving healthcare landscape.

Summary auto-generated by AI from the original publisher's content. Editorial standards.